Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) are up 17.3%, positioning for a new 52-week high of $40.99 if the gains should hold into Wednesday. The stock just came off an evening-session halt after the company said it received FDA marketing approval for MONOVISC, a single injection supplement to synovial fluid of the osteoarthritic joint, used…
Shares of Orexigen Therapeutics (NASDAQ:OREX) slipped in Tuesday’s pre-market session, after the developer of drug treatments for obesity and related disorders said it received a Day 120 List of Questions regarding the marketing authorization application for its NB32 weight-loss drug candidate from the European Medicines Agency’s Committee for Medicinal Products for Human Use. The company…
CoreLogic (NYSE: CLGX) announced that intends to divest its Asset Management and Processing Solutions segment, the area of its business that offers services to banks that allow them to handle their portfolio of foreclosed properties. The segment will now be classified as held for sale, and the company will take a noncash impairment charge of…
Equinix (NASDAQ:EQIX) reported solid Q4 results, modestly ahead of the Street and management’s guidance. Based on recurring FCF estimates, the market is already pricing in a favorable REIT conversion ruling, with shares trading at a modest premium to other REITs. Moreover, if the company does not receive a positive ruling, analysts see significant downside in…
EOPN reported fiscal second quarter 2014 results last night, delivering total revenue and subscription that met our forecast while non-GAAP EPS of $(0.10) beat our (and the Street’s) estimate by a nickel. While the important metrics of subscription revenue and bookings guidance for FY14 remain intact, investors are likely to focus on the meaningfully lowered…
Following in the footsteps of comparable companies, Diodes reported in-line 3Q13 results but also provided below-consensus 4Q13 revenue guidance. Management’s 4Q13 revenue guidance of -5.5% quarter over quarter (midpoint) is an indication of weaker market conditions and not indicative of the company losing market share. We are sticking with our Buy rating as we believe…
